P5091 is a selective and potent ubiquitin-specific protease 7 (USP7) inhibitor with an EC50 of 4.2 μM, similar to that of USP47.

 

Brand: BCM

 

Target: DUB

 

Signaling Pathways: Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Ubiquitination

 

In Vitro: P5091 in combination with Lenalidomide,HDAC inhibitors SAHA, or Dexamethasone showed synergistic antimm activity. In animal tumor model studies,P005091 is well tolerated, inhibits tumor growth and prolongs survival.

 

In Vivo: P5091 acts on animal tumor models, is well tolerated, inhibits tumor growth, and prolongs animal life. P5091 in combination with Lenalidomide, the HDAC inhibitor SAHA, or Dexamethasone triggers synergistic anti-MM activity.

 

Boiling Point: 452.4±45.0 °C(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

GHS: GHS06

 

Isomeric SMILES: CC(=O)C1=CC(=C(S1)SC2=C(C(=CC=C2)Cl)Cl)[N+](=O)[O-]  

 

InChIKey: LKZLGMAAKNEGCH-UHFFFAOYSA-N  

 

InChI: InChI=1S/C12H7Cl2NO3S2/c1-6(16)10-5-8(15(17)18)12(20-10)19-9-4-2-3-7(13)11(9)14/h2-5H,1H3

 

Attribute
[Chem Name]	1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone
[Synonym]	P5091; P005091
[CAS No.]	882257-11-6
[MDL No.]	MFCD00123202
[Formula]	C12H7Cl2NO3S2
[Molecular]	348.22
[Form]	Light yellow to dark yellow powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag